


Handbook of

# ANALYTICAL VALIDATION



Michael E. Swartz  
Ira S. Krull



CRC Press  
Taylor & Francis Group

Handbook of

---

# ANALYTICAL VALIDATION

---

Michael E. Swartz  
Ira S. Krull




CRC Press

Taylor & Francis Group

Boca Raton London New York

---

CRC Press is an imprint of the  
Taylor & Francis Group, an **Informa** business



CRC Press  
Taylor & Francis Group  
6000 Broken Sound Parkway NW, Suite 300  
Boca Raton, FL 33487-2742

© 2012 by Taylor & Francis Group, LLC  
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed in the United States of America on acid-free paper  
Version Date: 20120309

International Standard Book Number: 978-0-8247-0689-0 (Hardback)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access [www.copyright.com](http://www.copyright.com) (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

**Trademark Notice:** Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

**Visit the Taylor & Francis Web site at**  
<http://www.taylorandfrancis.com>

**and the CRC Press Web site at**  
<http://www.crcpress.com>

---

# Contents

Preface.....	xiii
<b>Chapter 1</b> Introduction to Analytical Method Validation.....	1
1.1 Introduction.....	1
1.2 Drug Development Process.....	1
1.3 FDA Hierarchy and Organization.....	3
1.4 International Conference on Harmonization.....	4
1.4.1 Structure of the ICH.....	5
1.4.1.1 European Commission of the European Union (EU).....	6
1.4.1.2 European Federation of Pharmaceutical Industries and Associations (EFPIA).....	6
1.4.1.3 Ministry of Health and Welfare, Japan (MHW).....	6
1.4.1.4 Japan Pharmaceutical Manufacturers Association (JPMA).....	6
1.4.1.5 US Food and Drug Administration (FDA).....	6
1.4.1.6 Pharmaceutical Research and Manufacturers of America (PhRMA).....	6
1.4.1.7 Observers.....	7
1.4.2 ICH Administration.....	7
1.4.3 ICH Harmonization Process.....	7
1.4.3.1 Step 1.....	7
1.4.3.2 Step 2.....	8
1.4.3.3 Step 3.....	8
1.4.3.4 Step 4.....	8
1.4.3.5 Step 5.....	8
1.4.4 ICH Harmonization Initiatives.....	8
1.5 AMV Guidance.....	9
1.5.1 Types of Analytical Procedures.....	11
1.5.2 Reference Standards.....	11
1.5.3 Certificate of Analysis.....	11
1.5.4 Characterization of a Reference Standard.....	12
1.5.5 Content and Format for Analytical Methods and Procedures.....	13
1.5.6 Content and Processing of the Method Validation Package.....	13
1.5.6.1 Selection and Shipment of Samples.....	13
1.5.6.2 Responsibilities.....	14
1.6 Validation Process.....	15

1.6.1	Software Validation.....	17
1.6.2	Analytical Instrument Qualification .....	17
1.6.3	System Suitability.....	18
1.7	Training .....	18
1.8	Conclusion .....	20
	References .....	20
<b>Chapter 2</b>	<b>Analytical Instrument Qualification .....</b>	<b>23</b>
2.1	Introduction .....	23
2.2	Components of Data Quality.....	23
2.3	AIQ Process.....	24
2.3.1	Design Qualification.....	24
2.3.2	Installation Qualification (IQ).....	25
2.3.3	Operational Qualification (OQ) .....	26
2.3.3.1	HPLC Pump Flow Rate Accuracy.....	27
2.3.3.2	Gradient Accuracy .....	28
2.3.3.3	Injector Accuracy.....	28
2.3.3.4	Column Oven and Auto Sampler Temperature .....	29
2.3.3.5	UV Detector Wavelength Accuracy and Linearity.....	30
2.3.4	Performance Qualification (PQ) .....	30
2.3.5	Preventative Maintenance and Repairs .....	32
2.4	Roles and Responsibilities.....	34
2.5	Software Validation and Change Control.....	34
2.6	AIQ Documentation .....	34
2.7	Instrument Categories .....	35
2.8	Conclusion .....	36
	References .....	36
<b>Chapter 3</b>	<b>HPLC Method Development and Optimization with Validation in Mind.....</b>	<b>37</b>
3.1	Introduction .....	37
3.2	HPLC Method Development Approaches .....	37
3.3	Method Goals .....	38
3.4	HPLC Method Development Instrumentation .....	39
3.4.1	HPLC Systems for Column and Method Scouting ....	44
3.4.2	Automated HPLC Method Development Systems.....	47
3.4.3	UHPLC in Method Development Systems.....	49
3.4.4	Solvent Management .....	50
3.4.5	Sample Management .....	51
3.4.6	Detection .....	51
3.4.7	Column Module.....	55
3.4.8	Columns for Method Development .....	56

3.4.9	Mobile Phase Considerations .....	57
3.5	Method Optimization .....	58
3.6	Summary .....	59
	References .....	59
<b>Chapter 4</b>	<b>Method Validation Basics .....</b>	<b>61</b>
4.1	Introduction .....	61
4.2	Method Validation Guidelines.....	61
4.3	Terms and Definitions .....	62
4.3.1	Accuracy.....	63
4.3.2	Precision.....	65
4.3.2.1	Repeatability .....	65
4.3.2.2	Intermediate Precision.....	65
4.3.2.3	Reproducibility .....	66
4.3.2.4	Ruggedness .....	67
4.3.3	Specificity.....	68
4.3.4	Detection Limit .....	70
4.3.5	Quantitation Limit.....	71
4.3.6	Linearity and Range.....	73
4.3.7	Robustness.....	74
4.4	Validation according to Method Type.....	75
4.5	Documentation .....	75
4.5.1	Validation Protocol.....	75
4.5.2	Test Method.....	76
4.5.3	Validation Report .....	77
4.6	Summary .....	78
	References .....	78
<b>Chapter 5</b>	<b>Robustness and System Suitability.....</b>	<b>81</b>
5.1	Introduction .....	81
5.2	Robustness Studies for Method Validation .....	81
5.3	Robustness Study Experimental Design.....	83
5.3.1	Screening Designs.....	83
5.3.1.1	Full Factorial Designs.....	84
5.3.1.2	Fractional Factorial Designs.....	84
5.3.1.3	Plackett–Burman Designs .....	86
5.3.2	Determining the Factors, Measuring the Results.....	86
5.4	Analyzing the Results.....	89
5.5	Documentation and Reporting .....	90
5.6	System Suitability Tests.....	91
5.7	System Suitability Standards.....	92
5.8	System Suitability Protocol.....	93
5.9	Method Adjustments to Meet System Suitability Requirements.....	94

5.9.1	pH Adjustments.....	96
5.9.2	Column Length, Diameter, and Particle Size Adjustments: Scaling the Separation.....	96
5.10	Conclusion .....	98
	References .....	99

## **Chapter 6** Setting Specifications and Investigating Out-of-Specification

	Results .....	101
6.1	Introduction .....	101
6.2	Guidance for Setting Specifications .....	101
6.3	General Concepts for Developing and Setting Specifications.....	102
6.3.1	Limited Data Available at Filing.....	102
6.3.2	Periodic or Skip Testing .....	103
6.3.3	Release versus Shelf-Life Acceptance Criteria .....	103
6.3.4	In-Process Tests.....	103
6.3.5	Parametric Release.....	103
6.3.6	Pharmacopeial Tests.....	103
6.4	Universal Tests/Criteria .....	104
6.5	Specific Tests/Criteria: New Drug Substances.....	104
6.5.1	Physicochemical Properties .....	104
6.5.2	Particle Size.....	104
6.5.3	Polymorphic Forms.....	104
6.5.4	Chiral-Drug Substance.....	105
6.5.5	Chiral-Drug Product .....	105
6.5.6	Water Content.....	105
6.5.7	Inorganic Impurities.....	105
6.5.8	Microbial Limits .....	106
6.6	Specific Tests/Criteria: New Solid Oral Drug Products.....	106
6.6.1	Dissolution.....	106
6.6.2	Disintegration .....	106
6.6.3	Hardness/Friability.....	106
6.6.4	Uniformity of Dosage Units.....	107
6.7	Specific Tests/Criteria: New Oral Liquid Drug Products.....	107
6.8	Specific Tests/Criteria: Parenteral Drug Products.....	107
6.9	Decision Trees .....	108
6.10	OOS Background.....	108
6.11	Preventing OOS Results .....	111
6.12	Identifying and Assessing OOS Test Results .....	111
6.13	Investigating OOS Test Results .....	113
6.13.1	General Investigative Principles.....	113
6.13.2	Laboratory Phase of an Investigation.....	113
6.13.2.1	Assignable Cause.....	114
6.13.2.2	No Assignable Cause/Retest.....	115

6.13.2.3	No Assignable Cause/Result Is Confirmed.....	115
6.13.3	Retesting.....	115
6.13.4	Resampling.....	115
6.13.5	Averaging (Resampling Testing Data).....	116
6.13.6	Outlier Tests.....	116
6.14	Concluding the OOS Investigation.....	116
6.15	Conclusion.....	117
	References.....	117
<b>Chapter 7</b>	<b>Validation by Type of Method.....</b>	<b>119</b>
7.1	Introduction.....	119
7.1.1	Category I Methods.....	119
7.1.2	Category II Methods.....	120
7.1.3	Category III Methods.....	121
7.1.4	Category IV Methods.....	121
7.2	Validation of Impurity Methods.....	121
7.2.1	Classification of Impurities.....	122
7.2.2	Impurity Method Validation Documentation.....	124
7.2.2.1	Reporting Impurity Content of API Batches.....	124
7.2.3	Specificity in Impurity Methods.....	125
7.2.4	Accuracy in Impurity Methods.....	126
7.3	Stability Indicating Method.....	126
7.3.1	Developing and Validating SIMS.....	127
7.3.1.1	Generating the Sample.....	127
7.3.1.2	Developing the LC Method.....	128
7.3.1.3	Manipulating Chromatographic Selectivity during Method Development..	129
7.3.1.4	Evaluating Specificity during SIM Development.....	131
7.3.1.5	New Technology for SIM Development ...	134
7.3.2	SIM Validation.....	135
7.4	Developing and Validating Dissolution Procedures.....	135
7.4.1	Qualification and Calibration.....	136
7.4.2	Dissolution Procedure Development.....	137
7.4.2.1	Dissolution Medium.....	137
7.4.2.2	Dissolution Apparatus.....	138
7.4.2.3	Dissolution Study Design.....	139
7.4.2.4	Assaying the Results.....	140
7.4.3	Dissolution Procedure Validation.....	141
7.4.3.1	Specificity/Placebo Interference.....	141
7.4.3.2	Linearity and Range.....	142
7.4.3.3	Accuracy and Recovery.....	142



	7.4.3.4	Precision .....	142
	7.4.3.5	Robustness .....	143
	7.4.3.6	Remaining Validation Tests.....	143
7.5		Bioanalytical Methods.....	143
	7.5.1	Reference Standard Preparation.....	145
	7.5.2	Bioanalytical Method Development and Validation ....	145
		7.5.2.1 Selectivity .....	145
		7.5.2.2 Accuracy, Precision, and Recovery .....	146
		7.5.2.3 Calibration/Standard Curve.....	146
		7.5.2.4 Bioanalytical Sample Stability .....	147
	7.5.3	Routine Application of the Bioanalytical Method ...	148
	7.5.4	Bioanalytical Method Documentation .....	150
7.6		Validating Peptide Mapping Methods.....	150
	7.6.1	Biocharacterization of Peptides.....	151
		7.6.1.1 Selective Cleavage of the Protein Peptide Bonds .....	151
		7.6.1.2 Chromatographic Separation.....	153
	7.6.2	Validation of Peptide Mapping Methods.....	154
		7.6.2.1 Robustness .....	154
		7.6.2.2 Limit of Detection (LOD).....	154
		7.6.2.3 Precision .....	155
		7.6.2.4 System Suitability .....	155
	7.6.3	Mass Spectrometry in Peptide Mapping .....	156
7.7		Cleaning Method Validation .....	157
	7.7.1	General Requirements.....	157
	7.7.2	Equipment Cleaning.....	158
		7.7.2.1 Sampling Methods.....	159
	7.7.3	Validating Cleaning Methods .....	159
	7.7.4	Setting Residue Limits .....	160
7.8		Conclusion .....	161
		References .....	162
<b>Chapter 8</b>		<b>Analytical Method Transfer .....</b>	<b>165</b>
	8.1	Introduction .....	165
	8.2	Terms, Definitions, and Responsibilities .....	165
	8.3	Analytical Method Transfer Options.....	166
		8.3.1 Comparative Testing.....	167
		8.3.2 Co-Validation between Laboratories.....	167
		8.3.3 Method Validation and Revalidation.....	167
		8.3.4 Transfer Waiver .....	167
	8.4	Elements of AMT .....	168
		8.4.1 Preapproved Test Plan Protocol .....	168
		8.4.2 Description of Method/Test Procedures .....	168
		8.4.3 Description and Rationale of Test Requirements....	168
		8.4.4 Acceptance Criteria.....	169

8.5	Documentation of Results: AMT Report .....	169
8.6	Potential AMT Pitfalls .....	169
8.6.1	Instrument Considerations .....	171
8.6.2	Column Considerations .....	172
8.6.3	General Considerations .....	172
8.7	Conclusion .....	172
	References .....	173
<b>Chapter 9</b>	<b>Implementing New Technology in a Regulated Environment .....</b>	<b>175</b>
9.1	Introduction .....	175
9.2	Changes to an Approved Method .....	175
9.3	What Constitutes a Change to a Method? .....	176
9.4	Implement an Existing Standard Method.....	177
9.4.1	Verification .....	177
9.4.1.1	Laboratory Personnel.....	178
9.4.1.2	Approved Procedure .....	178
9.4.1.3	Verification Documentation.....	178
9.4.1.4	Verification Process Examples .....	179
9.5	Implement an Existing Standard Method with Adjustments .....	180
9.6	Implement an Existing Standard Method with Changes.....	181
9.7	Conclusion .....	182
	References .....	182
	<b>Glossary of Terms Related to Chromatographic Method Validation.....</b>	<b>183</b>
	<b>Appendix: Example Method Validation Protocol.....</b>	<b>191</b>
	<b>Index.....</b>	<b>199</b>